DAPA ACT HF-TIMI 68 is an investigator-initiated, randomized, double-blind, placebo-controlled trial in patients with heart failure who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin on the clinical outcomes of cardiovascular death or worsening heart failure.
DAPA ACT HF on ClinicalTrials.gov
TIMI STUDY GROUP 